Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Systematic review shows GLP 1 receptor agonists trials rarely assess dietary intake, highlighting a major evidence gap in nutrition outcomes.
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices. Electronic patient-reported outcome-based weight management versus usual care ...
A landmark Lancet analysis of more than 150,000 trial participants challenges decades of statin side-effect warnings and calls for updated drug labels grounded in randomized evidence. Study: ...
Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results